2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cyclophosphamide
2067
Radiotherapy
1990
Cisplatin
1856
Carboplatin
1560
Gemcitabine
1454
Paclitaxel
1320
Bevacizumab
1320
pembrolizumab
1238
Docetaxel
1227
Oxaliplatin
1184
Capecitabine
1178
Fluorouracil
1083
Dexamethasone
979
Magnetic Resonance Spectroscopy
971
Nivolumab
936
Rituximab
929
Drug Therapy
915
Surveys and Questionnaires
899
Doxorubicin
845
Etoposide
843
Radiosurgery
816
Blood Specimen Collection
816
Irinotecan
784
Cytarabine
743
fludarabine
726
Leucovorin
684
Surgical Procedures, Operative
640
Lenalidomide
618
Biopsy
594
fludarabine phosphate
569
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled
NCT02667925
2016-10-11
ISOTOVE
Centre Jean Perrin
Phase NA
Withdrawn